<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS192866</article-id><article-id pub-id-type="doi">10.1101/2023.12.15.571872</article-id><article-id pub-id-type="archive">PPR775004</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Single-cell DNA sequencing reveals pervasive positive selection throughout preleukemic evolution</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Poon</surname><given-names>Gladys</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vedi</surname><given-names>Aditi</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sanders</surname><given-names>Mathijs</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Laurenti</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Valk</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Blundell</surname><given-names>Jamie R.</given-names></name></contrib></contrib-group><aff id="A1"><label>1</label>Early Cancer Institute, University of Cambridge, UK</aff><aff id="A2"><label>2</label>Wellcome – MRC Cambridge Stem Cell Institute, University of Cambridge, UK</aff><aff id="A3"><label>3</label>Cambridge University Hospital NHS Foundation Trust, UK</aff><aff id="A4"><label>4</label>Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands</aff><pub-date pub-type="nihms-submitted"><day>17</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>16</day><month>12</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">The representation of driver mutations in preleukemic haematopoietic stem cells (pHSCs) provides a window into the somatic evolution that precedes Acute Myeloid Leukemia (AML). Here, we isolate pHSCs from the bone marrow of 16 patients diagnosed with AML and perform single-cell DNA sequencing on thousands of cells to reconstruct phylogenetic trees of the major driver clones in each patient. We develop a computational framework that can infer levels of positive selection op-erating during preleukemic evolution from the statistical properties of these phylogenetic trees. Combining these data with 67 previously published phylogenetic trees, we find that the highly variable structures of preleukemic trees emerge naturally from a simple model of somatic evolution in which there is pervasive positive selection acting throughout the disease trajectory. We infer that selective advantages of preleukemic clones are typically in the range of 9%-24% per year, but vary considerably between individuals. At these level of positive selection, we show that the identification of early multiple-mutant clones identifies individuals at risk of future AML.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Large cancer genome sequencing efforts over the last 20 years have revealed that most cancers harbour multiple clonal driver mutations at diagnosis<sup><xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref></sup>. These mutations are sometimes acquired decades before the emergence of the first malignant cell<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup>. How the full complement of driver mutations is acquired in a single cell over a human lifespan, however, is not fully understood. Early multi-hit theories of cancer considering mutation acquisition as the key factor seemingly capture the age-incidence relationships across a range of cancers<sup><xref ref-type="bibr" rid="R6">6</xref></sup>. However, using estimates of somatic mutation rates<sup><xref ref-type="bibr" rid="R7">7</xref></sup> and stem cell numbers<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref></sup> these theories struggle to provide plausible estimates for overall cancer incidence<sup><xref ref-type="bibr" rid="R10">10</xref></sup>.</p><p id="P3">Work over the last decade using deep bulk sequencing has shown that there is positive selection acting on mutations in cancer-associated genes across a range of healthy tissues<sup><xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R21">21</xref></sup>. This suggests that positive selection may act throughout the entire multi-hit trajectory of cancer. However, because of the inherent challenges in measuring precancerous evolution, the predictions of this conceptual idea have not been quantitatively tested.</p><p id="P4">Single-cell sequencing from multiple cells in a population can provide a quantitative picture of the evolutionary history of the population by using somatic mutations as unique lineage markers for building phylogenetic trees<sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R22">22</xref>–<xref ref-type="bibr" rid="R24">24</xref></sup>. The haematopoietic system provides an ideal model for using single-cell approaches as haematopoietic stem cells (HSCs) can be easily isolated and sequenced. These approaches have revealed that large numbers of HSCs maintain the blood in healthy individuals<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>, that the driver events of certain blood cancers can be acquired in utero<sup><xref ref-type="bibr" rid="R5">5</xref></sup> and that there is extensive clonal heterogeneity in acute myeloid leukaemia (AML)<sup><xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R28">28</xref></sup>. An innovative approach to studying pre-cancerous evolution is through the isolation of ostensibly healthy preleukemic HSCs (pHSCs) from AML patients at diagnosis. By coupling this idea with single-cell sequencing the step-wise nature of preleukemic evolution and how preleukemic clones can seed relapse post therapy has been previously demonstrated<sup><xref ref-type="bibr" rid="R29">29</xref></sup>. However, the quantitative information encoded in the preleukemic phylogenetic trees have not been fully exploited to understand how levels of positive selection operate during preleukemic evolution. Here we hypothesize that the statistical properties of phylogenetic trees across many AML patients could reveal levels of positive selection operating during preleukemic evolution and how those levels vary among individuals.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Single-cell phylogenies from preleukemic HSCs</title><p id="P5">To construct phylogenetic trees from preleukemic HSCs (pHSCs) we obtained bone marrow aspirate samples from 16 AML patients collected at diagnosis from the multicenter HOVONSAKK clinical trials (see ‘Sample selection’ in <xref ref-type="supplementary-material" rid="SD1">Supplementary note 1</xref>). To minimize inter-patient variation we selected samples with a genetically restricted AML genotype (<italic>DNMT3A</italic><sup>mut</sup>/<italic>NPM1</italic><sup>mut</sup>). Preleukemic HSCs were isolated by FACS sorting (<xref ref-type="fig" rid="F1">Figure 1A</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary note 1</xref>). We then performed single-cell DNA sequencing of these pHSCs targeting 45 myeloid genes using the Tapestri platform (Mission Bio). Combining this data with a high-confidence set of driver mutations identified by bulk sequencing of each bone marrow aspirate sample, we were able to genotype a total of 4013 HSCs (range 7 — 988 per sample) for the reconstruction of phylogenetic trees. Individual cells from single-cell sequencing were then assigned to clones based on the presence or absence of these driver mutations, forming a phylogenetic tree based on driver mutations for each sample (<xref ref-type="supplementary-material" rid="SD1">Supplementary note 1</xref>).</p><p id="P6">Phylogenies enabled us to reconstruct how AML evolves from initially healthy HSCs. Across the 16 individuals analyzed we found that the AML clones (red stars, <xref ref-type="fig" rid="F1">Figure 1</xref>) most commonly harbour 3 (<italic>n</italic> = 8) or 4 (<italic>n</italic> = 6) driver mutations (<xref ref-type="fig" rid="F1">Figure 1B-E</xref>). The most commonly co-occurring drivers alongside the <italic>DNMT3A</italic> and <italic>NPM1</italic> mutations were in <italic>NRAS</italic> (<italic>n</italic> = 12), <italic>FLT3</italic> (<italic>n</italic> = 11), <italic>TET2</italic> (<italic>n</italic> = 8), <italic>IDH1</italic>/<italic>IDH2</italic> (<italic>n =</italic> 5), <italic>RAD21</italic> (<italic>n</italic> = 4), and <italic>WT1</italic> (<italic>n</italic> = 4) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1-4</xref>). In all of the samples where the single-cell level data enabled us to determine the order of mutation acquisition, we found that <italic>DNMT3A</italic> preceded <italic>NPM1</italic>. <italic>DNMT3A</italic> is typically the first mutation acquired along the evolutionary branch to the AML clone, in agreement with previous findings<sup><xref ref-type="bibr" rid="R30">30</xref></sup>. Mutations in the RAS pathway (<italic>FLT3</italic>, <italic>NRAS</italic>), when observed in our data, are usually late driver events either the 3rd or the 4th “hit”. Acquisition of <italic>NPM1</italic> is usually secondary to <italic>DNMT3A</italic> but earlier than <italic>FLT3</italic> or <italic>NRAS</italic><sup><xref ref-type="bibr" rid="R30">30</xref></sup>. Mutations in <italic>IDH1/2</italic> and <italic>TET2</italic> were found to be mutually exclusive on the ancestral branch of the AML blasts, consistent with previous observations<sup><xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup>.</p><p id="P7">The trees also revealed highly diverse patterns of preleukemic evolution. In approximately a third of cases (6/16) we observed evidence of branched evolution indicating multiple evolutionary paths to higher fitness in HSCs. Our data suggests that these parallel competing lineages can coexist for a considerable time as the coalescence events can occur early in a tree. In the remaining 10 samples, we observed patterns of linear evolution which may indicate strong preferences for particular evolutionary paths in the fitness landscape. In addition to the qualitative differences among the trees we also observed clear quantitative diversity at the level of clone sizes. In approximately a third of cases (6/16) we observed that wild-type HSCs – cells carrying no detectable driver mutations – remain the dominant clone in the HSC pool at the time of diagnosis (<xref ref-type="fig" rid="F1">Figure 1B, C</xref> and e.g. ID12565 and ID2261 in E). On the other hand, in 5 cases we observed that the wild-type HSCs have largely been out-competed by later occurring clones carrying multiple driver mutations (<xref ref-type="fig" rid="F1">Figure 1D</xref>, e.g. ID4334 and ID32963 in E). In the remaining samples there appears to be coexistence of intermediate clones – harbouring different numbers of driver mutations – at similar clone sizes (ID47668 and ID26833R in <xref ref-type="fig" rid="F1">Figure 1E</xref>).</p></sec><sec id="S4"><title>Inferring positive selection from phylogenies</title><p id="P8">The clone size statistics of the phylogenetic trees are the outcome of clonal competition, mutation and stochasticity during preleukemic evolution. We reasoned that the diverse patterns observed in the AML trees may emerge naturally due to these three interacting elements in the evolutionary dynamics, in-dependent of the specific details of the mutations involved. To test this hypothesis we developed a simplified model of preleukemic evolution which is informed by experimental observations<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R33">33</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup> (<xref ref-type="fig" rid="F2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary note 2</xref>).</p><p id="P9">To avoid over-fitting to the data we impose the simplifying assumption that each driver mutation is acquired at the same rate <italic>µ</italic> and confers the same advantage <italic>s</italic> to cells regardless of mutation identity and the effects of driver mutations combine additively. Transformation to AML occurs once <italic>k</italic> driver mutations occur in the same cell (red clone, <italic>k</italic> = 4 case in <xref ref-type="fig" rid="F2">Figure 2B</xref>). This framework can be used to simulate phylogenies of HSCs at the time of transformation. In order to compare the quantitative patterns observed in simulated trees to those experimentally measured in the AML cases, we considered the clone size vector, <italic><bold>n</bold></italic> = (<italic>n</italic><sub>0</sub>, <italic>n</italic><sub>1</sub>, … , <italic>n</italic><sub><italic>k</italic>−1</sub>), which quantifies the clonal frequencies of the wild-type, single mutant, double mutant etc. clones along the main evolutionary branch ancestral to the AML clone at the time of transformation (<xref ref-type="fig" rid="F2">Figure 2C</xref>). The statistical properties of the clone size vector, <italic><bold>n</bold></italic>, reflect different levels of selection (<italic>s</italic>) operating during preleukemic evolution (<xref ref-type="supplementary-material" rid="SD1">Supplementary figure S17</xref>).</p><p id="P10">We used our model to perform in excess of a billion stochastic simulations across a range of fitness effects and mutation rates consistent with previously inferred values<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R37">37</xref></sup> (<xref ref-type="fig" rid="F2">Figure 2D</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary note 2</xref>). In these simulations we considered a ‘virtual AML’ to occur when a clone that carries <italic>k</italic> = 3 or <italic>k = 4</italic> driver mutations emerges before 80 years, in line with the diagnosis ages in our cohort. We recorded 4000 <italic>k</italic> = 3 and 4000 <italic>k</italic> = 4 ‘virtual AMLs’ for every selection strength considered and used them for tree comparison with observed clone size vectors.</p><p id="P11">Of the sixteen reconstructed trees from our single-cell experiments, twelve were unambiguously genotyped for all driver mutations. We identified the best-matched ‘virtual AML’ for every one of these observed clone size vectors and calculated the total similarity over all the best-matched ‘virtual AMLs’ across a range of selection strengths (<xref ref-type="fig" rid="F2">Figure 2E and F</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary note 2</xref>). This provides an estimate for the likelihood that the set of observed trees is generated from preleukemic evolution driven by the assumed selection strength <italic>s</italic>. We found that the statistical properties of the observed tree set are consistent with simulated tree patterns generated under moderate to strong selection (<italic>s</italic> ≥ 9% per year). These selection strengths cause intermediate clones to expand to high cell fractions and lead to the co-existence of wildtype and multiple mutant clones in the HSC pool at diagnosis. Neutral evolution (<italic>s</italic> = 0%) produces highly homogeneous sets of ‘virtual AML’ tree patterns where the preleukemic stem cell population is always dominated by the wild-type clone. This is inconsistent with the set of our experimentally observed trees, suggesting that stochastic acquisition of mutations alone cannot account for the emergence of AML.</p><p id="P12">Validation using an independent single-cell dataset. To test how well these findings generalize to other AML cases, we considered 27 AML trees from an independent single-cell study<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. We extracted clone size vectors, <italic><bold>n</bold></italic>, from each of these cases and performed the same procedure for inferring levels of positive selection (<xref ref-type="supplementary-material" rid="SD1">Supplementary note 2</xref>). As was observed from our single-cell data, the statistics of the clone size vectors are highly variable with some cases exhibiting the dominance of wild-type clones and others the co-existence of intermediate clones. Consistent with our previous findings, these trees cannot be explained by a model of neutral evolution (left panel, <xref ref-type="fig" rid="F3">Figure 3</xref>). Models of evolution driven by moderate levels of positive selection (9% &lt; <italic>s</italic> &lt; 24% per year) produce clone size vectors that are in close agreement with those observed in the 27 trees (middle panel, <xref ref-type="fig" rid="F3">Figure 3</xref>). Increasing selection strengths even further (<italic>s &gt;</italic> 24% per year) produces clone size vectors which become less consistent with the data (right panel, <xref ref-type="fig" rid="F3">Figure 3</xref>). The selection strengths implied by these data are therefore consistent with the selection strengths inferred from our single-cell data. These findings generalize to cases that were driven by 4 driver mutations (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S9</xref>) as well as trees that show considerable branching (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S8</xref>).</p></sec><sec id="S5"><title>Variation in selection strengths across individuals</title><p id="P13">To evaluate whether there is evidence of variation in levels of positive selection across individuals, we extracted all <italic>k</italic> = 3 and <italic>k</italic> = 4 AML trees (67 in total) from Morita et al.<sup><xref ref-type="bibr" rid="R27">27</xref></sup> and combined these with our own experimentally observed trees. To estimate the most likely selection levels that drove the preleukemic evolution in each of these 80 trees, we identified the 100 most similar ‘virtual AMLs’ for each case and considered the distribution of the selection strengths that produced them (<xref ref-type="fig" rid="F4">Figure 4A</xref>).</p><p id="P14">The majority of trees are consistent with preleukemic evolution driven by selection strengths in the range of <italic>s</italic> = 9% − 24% per year (<xref ref-type="fig" rid="F4">Figure 4B</xref>). However, we observe clear variation in selection strengths across the 80 trees. Trees in which wild-type clones remain dominant at diagnosis (upper rows, <xref ref-type="fig" rid="F4">Figure 4B</xref>) are consistent with weaker selection strengths. In these cases our framework is confident on the inferred levels of selection: the best-matched ‘virtual AMLs’ consistently fall onto a narrow range of ‘<italic>s</italic>’. For example, our inference using this framework strongly suggests that the preleukemic evolution in ID12565 and ID2225 was driven by weak selection strengths at <italic>s</italic> ≈ 3 − 9% per year. Trees with a diverse co-existence of multiple-mutant clones (lower rows, <xref ref-type="fig" rid="F4">Figure 4B</xref>) are inferred to have been driven by stronger levels of positive selection. In these cases, however, the framework is less confident in its inferences: the best-matched ‘virtual AMLs’ come from a wider range of ‘<italic>s</italic>’ (ID32963 and ID7328, <xref ref-type="fig" rid="F4">Figure 4B</xref>).</p><p id="P15">To assess how finite sampling impacts our inferences, we trained neural networks on subsampled ‘virtual AMLs’ to infer selection strengths <italic>s</italic> and mutation rates <italic>µ</italic> from a single tree (<xref ref-type="supplementary-material" rid="SD1">Supplementary note 3</xref>). Applying these neural networks to our experimentally observed trees we found that the inferred selection levels are broadly consistent with our previous inferences based on clone-size similarity (<xref ref-type="supplementary-material" rid="SD1">Supplementary figure S15</xref>). This indicates that subsampling introduced by finite numbers of pHSCs only influences the inferred levels of selection where cell numbers are small.</p></sec><sec id="S6"><title>In silico modelling identifies features of future AML risk</title><p id="P16">Our finding that most observed AML trees appear to be consistent with moderate selection strengths suggests that preleukemic clones expand over timescales of decades and could be used to identify individuals at high risk of developing AML. However, a key challenge in identifying robust predictors of risk for rare cancers such as AML is in understanding how rare these features are in individuals not destined to develop the cancer. Using our <italic>in silico</italic> model we are able to compare the evolutionary trajectories that precede ‘virtual AMLs’ (<xref ref-type="fig" rid="F5">Figure 5A</xref>) to the trajectories observed in hundreds of thousands of simulated individuals who never develop ‘virtual AML’. In an HSC population of ~ 10<sup>5</sup> stem cells<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref></sup> where driver mutations occur at rate of ~ 10<sup>−5</sup> per year<sup><xref ref-type="bibr" rid="R37">37</xref></sup>, clones carrying single driver mutations occur routinely in both future AML cases and controls (orange shading, <xref ref-type="fig" rid="F5">Figure 5B and &gt;C</xref>). This is consistent with what is known about the prevalence of clonal haematopoiesis in healthy individuals<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup> and suggests that the detection of clones carrying a single driver mutation is unlikely to be a robust predictor of AML. However, the emergence of double mutant clones (i.e. cells harbouring two driver mutations) is predicted to be rare in healthy individuals under the age of 30. In contrast, more than half of future ‘virtual AML’ cases have already acquired a double mutant by the same age (green shading, <xref ref-type="fig" rid="F5">Figure 5B and C</xref>). While the relative risk conferred by the emergence of a double mutant is considerable, its absolute risk remains modest (<xref ref-type="fig" rid="F5">Figure 5D</xref>) (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S16</xref> for <italic>k</italic> = 3). The emergence of a triple mutant clones before the age of 50 confers both a large relative and absolute risk of developing a four-hit ‘virtual AML’ before age 70.</p><p id="P17">In summary, by simulating the evolutionary dynamics using parameters inferred from the experimental trees and examining large numbers of virtual AML cases and controls one can learn the general features which identify future AML cases. Multiple-mutant clones (carrying &gt;1 driver mutation in the same lineage) that arise anomalously early (e.g. in individuals &lt; 30 years of age) carry a considerable risk of transforming to AML.</p></sec></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P18">We have shown that preleukemic clones, which harbour subsets of the driver mutations present in the AML clone, coexist in the HSC/multipotent progenitor (MPP) pool at the time of AML diagnosis. Single-cell sequencing of these clones enabled the construction of phylogenetic trees depicting the clonal evolution that occurs in HSCs antecedent to AML. We found that clone size patterns revealed by the phylogenetic trees were highly variable across individuals. Using evolutionary modelling we showed that these diverse patterns are representative outcomes of somatic evolution that is driven by pervasive positive selection. The major implication of these inferred selection strengths is that preleukemic clones expand from low frequencies to become detectable decades prior to the AML transformation event. This provides a long window of opportunity for risk prediction and potential intervention. Our inferences are based on the assumption that selection strengths remain constant throughout life. However we cannot rule out that selection pressures may vary in time due to extrinsic factors including ageing<sup><xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R38">38</xref></sup>, cytotoxic therapies and smoking<sup><xref ref-type="bibr" rid="R37">37</xref></sup>.</p><p id="P19">There are a number of technical limitations in our work that need to be considered when interpreting the results. Chief amongst these is our premise that the sizes of preleukemic clones are determined only by the forces of selection, mutation and drift operating during preleukemic evolution. One important possible technical effect is that clones sizes may also reflect biases introduced during the experimental process of isolating and sequencing HSCs. Specifically, if the immunophenotype of the HSC co-varies consistently with the presence of a particular driver mutation, this could cause systematic biases in our inference of selection strengths. To evaluate the influence of this effect we performed a technical replicate of our experimental procedure on the bone marrow aspirates from one patient (ID12565 in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S15</xref>) and confirmed that our model inferences were unaffected. The validation of our inferences on an independent single-cell dataset<sup><xref ref-type="bibr" rid="R27">27</xref></sup> generated from unsorted samples also suggests that the experimentally observed clone size vectors are not primarily dominated by systematic biases introduced during the isolation of pHSCs.</p><p id="P20">Whilst the conceptual model presented here is clearly an oversimplification of the underlying biology (neglecting epistasis between driver mutations, extrinsic perturbations altering the fitness of clones<sup><xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R39">39</xref></sup>, explicit effects of ageing<sup><xref ref-type="bibr" rid="R38">38</xref></sup> and many other factors) it nevertheless highlights that the patterns observed in the phylogenetic trees can be explained by a far simpler model which has as its defining feature the requirement for positive selection on intermediate clones. In order to focus on the general behaviours that emerge from positive selection, the model intentionally ignores differences between driver mutations (i.e. all drivers confer the same selective advantage to HSCs and their effects combine additively in fitness effect). This simplified model highlights that the divergence between healthy and pre-malignant evolutionary dynamics in blood usually occurs due to the emergence of an anomalously early double mutant clone. We propose that the detection of rare clones harbouring two driver mutations within a single cell in young adults could provide a rational basis for identifying individuals at high risk of progression to AML. This conceptual framework may also provide a potential route to resolving the apparent discrepancies between models of oncogenesis based on stochastic mutation accumulation and bad luck<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R40">40</xref>–<xref ref-type="bibr" rid="R42">42</xref></sup>, the detection of driver mutations in healthy tissues<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R43">43</xref>–<xref ref-type="bibr" rid="R45">45</xref></sup> and the observed lifetime risk of AML (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S18</xref>).</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS192866-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d28aAdDbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S8"><title>Acknowledgements</title><p>We thank Daniel Fisher for helpful discussions and the team at Mission Bio for their technical support throughout this project. We thank all members of the Blundell lab for input. Y.P.G.P and J.R.B are funded by a UKRI Future Leaders Fellowship and by the CRUK Cambridge Cancer Centre. We thank Cambridge NIHR BRC Cell Phenotyping Hub for flow cytometry sorting. E.L. is funded by a Wellcome – Royal Society Sir Henry Dale Fellowship 107630/Z/15/Z and A.V. by Gates Cambridge Trust PhD Scholarship (10350885) until 2022. Work in E.L. group is funded by BIRAX (47BX16ELLS) and core support grants by Wellcome and Medical Research Council (MRC) to the Wellcome-MRC Cambridge Stem Cell Institute 203151/Z/16/Z and the UKRI Medical Research Council (MC_PC_17230). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.</p></ack><sec id="S9" sec-type="data-availability"><title>Data and code availability</title><p id="P21">All code used in this study are available on the <ext-link ext-link-type="uri" xlink:href="https://github.com/blundelllab">Blundell lab Github page</ext-link>. The raw sequencing data will be deposited on the European Nucleotide Archive.</p></sec><ref-list><ref id="R1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Jennings</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Pan-cancer analysis of whole genomes</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>578</volume><fpage>82</fpage><lpage>93</lpage><issue>7793</issue><pub-id pub-id-type="pmcid">PMC7025898</pub-id><pub-id pub-id-type="pmid">32025007</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-1969-6</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>TJ</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><etal/></person-group><collab>Cancer Genome Atlas Research Network</collab><article-title>Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</article-title><volume>368</volume><fpage>2059</fpage><lpage>2074</lpage><pub-id pub-id-type="pmcid">PMC3767041</pub-id><pub-id pub-id-type="pmid">23634996</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1301689</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mutational landscape and significance across 12 major cancer types</article-title><publisher-name>Nature Publishing Group.</publisher-name><volume>502</volume><issue>7471</issue><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="pmcid">PMC3927368</pub-id><pub-id pub-id-type="pmid">24132290</pub-id><pub-id pub-id-type="doi">10.1038/nature12634</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Jolly</surname><given-names>C</given-names></name><name><surname>Leshchiner</surname><given-names>I</given-names></name><name><surname>Dentro</surname><given-names>SC</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><etal/></person-group><article-title>The evolutionary history of 2,658 cancers</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>578</volume><issue>7793</issue><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="pmcid">PMC7054212</pub-id><pub-id pub-id-type="pmid">32025013</pub-id><pub-id pub-id-type="doi">10.1038/s41586-019-1907-7</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Moore</surname><given-names>L</given-names></name><name><surname>Baxter</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Life histories of myeloproliferative neoplasms inferred from phylogenies</article-title><volume>602</volume><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">35058638</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>P</given-names></name><name><surname>Doll</surname><given-names>R</given-names></name></person-group><article-title>The age distribution of cancer and a multistage theory of carcinogenesis</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15522923</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araten</surname><given-names>DJ</given-names></name><name><surname>Golde</surname><given-names>DW</given-names></name><name><surname>Zhang</surname><given-names>RH</given-names></name><name><surname>Thaler</surname><given-names>HT</given-names></name><name><surname>Gargiulo</surname><given-names>L</given-names></name><etal/></person-group><article-title>A quantitative measurement of the human somatic mutation rate</article-title><volume>65</volume><fpage>8111</fpage><lpage>8117</lpage><pub-id pub-id-type="pmid">16166284</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee-Six</surname><given-names>H</given-names></name><name><surname>Øbro</surname><given-names>NF</given-names></name><name><surname>Shepherd</surname><given-names>MS</given-names></name><name><surname>Grossmann</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Population dynamics of normal human blood inferred from somatic mutations</article-title><volume>561</volume><fpage>473</fpage><pub-id pub-id-type="pmcid">PMC6163040</pub-id><pub-id pub-id-type="pmid">30185910</pub-id><pub-id pub-id-type="doi">10.1038/s41586-018-0497-0</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>CJ</given-names></name><name><surname>Papula</surname><given-names>AL</given-names></name><name><surname>Poon</surname><given-names>GYP</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name><name><surname>Young</surname><given-names>AL</given-names></name><etal/></person-group><article-title>The evolutionary dynamics and fitness landscape of clonal hematopoiesis</article-title><volume>367</volume><fpage>1449</fpage><lpage>1454</lpage><publisher-name>American Association for the Advancement of Science Section: Research Article</publisher-name><pub-id pub-id-type="pmid">32217721</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durrett</surname><given-names>R</given-names></name><name><surname>Moseley</surname><given-names>S</given-names></name></person-group><article-title>Evolution of resistance and progression to disease during clonal expansion of cancer</article-title><volume>77</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">19896491</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>MJ</given-names></name><name><surname>Sottoriva</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>TA</given-names></name></person-group><article-title>Measuring clonal evolution in cancer with genomics</article-title><volume>20</volume><fpage>309</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">31059289</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Raine</surname><given-names>KM</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Dawson</surname><given-names>KJ</given-names></name><name><surname>Haase</surname><given-names>K</given-names></name><etal/></person-group><article-title>Universal patterns of selection in cancer and somatic tissues</article-title><volume>171</volume><fpage>1029</fpage><lpage>1041</lpage><elocation-id>e21</elocation-id><pub-id pub-id-type="pmcid">PMC5720395</pub-id><pub-id pub-id-type="pmid">29056346</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>GYP</given-names></name><name><surname>Watson</surname><given-names>CJ</given-names></name><name><surname>Fisher</surname><given-names>DS</given-names></name><name><surname>Blundell</surname><given-names>JR</given-names></name></person-group><article-title>Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>53</volume><issue>11</issue><fpage>1597</fpage><lpage>1605</lpage><pub-id pub-id-type="pmid">34737428</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>G</given-names></name><name><surname>Kähler</surname><given-names>AK</given-names></name><name><surname>Handsaker</surname><given-names>RE</given-names></name><name><surname>Lindberg</surname><given-names>J</given-names></name><name><surname>Rose</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence</article-title><volume>371</volume><fpage>2477</fpage><lpage>2487</lpage><pub-id pub-id-type="pmcid">PMC4290021</pub-id><pub-id pub-id-type="pmid">25426838</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1409405</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>S</given-names></name><name><surname>Fontanillas</surname><given-names>P</given-names></name><name><surname>Flannick</surname><given-names>J</given-names></name><name><surname>Manning</surname><given-names>A</given-names></name><name><surname>Grauman</surname><given-names>PV</given-names></name><etal/></person-group><article-title>Age-related clonal hematopoiesis associated with adverse outcomes</article-title><volume>371</volume><fpage>2488</fpage><lpage>2498</lpage><pub-id pub-id-type="pmcid">PMC4306669</pub-id><pub-id pub-id-type="pmid">25426837</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1408617</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>PR</given-names></name><name><surname>Genovese</surname><given-names>G</given-names></name><name><surname>Handsaker</surname><given-names>RE</given-names></name><name><surname>Finucane</surname><given-names>HK</given-names></name><name><surname>Reshef</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations</article-title><volume>559</volume><fpage>350</fpage><pub-id pub-id-type="pmcid">PMC6054542</pub-id><pub-id pub-id-type="pmid">29995854</pub-id><pub-id pub-id-type="doi">10.1038/s41586-018-0321-x</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>PR</given-names></name><name><surname>Genovese</surname><given-names>G</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name></person-group><article-title>Monogenic and polygenic inheritance become instruments for clonal selection</article-title><publisher-name>Nature Publishing Group</publisher-name><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmcid">PMC7415571</pub-id><pub-id pub-id-type="pmid">32581363</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2430-6</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Roshan</surname><given-names>A</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Tumor evolution. high burden and pervasive positive selection of somatic mutations in normal human skin</article-title><volume>348</volume><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="pmcid">PMC4471149</pub-id><pub-id pub-id-type="pmid">25999502</pub-id><pub-id pub-id-type="doi">10.1126/science.aaa6806</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Fowler</surname><given-names>JC</given-names></name><name><surname>Wabik</surname><given-names>A</given-names></name><name><surname>Lawson</surname><given-names>ARJ</given-names></name><name><surname>Abascal</surname><given-names>F</given-names></name><etal/></person-group><article-title>Somatic mutant clones colonize the human esophagus with age</article-title><volume>362</volume><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="pmcid">PMC6298579</pub-id><pub-id pub-id-type="pmid">30337457</pub-id><pub-id pub-id-type="doi">10.1126/science.aau3879</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>ARJ</given-names></name><name><surname>Abascal</surname><given-names>F</given-names></name><name><surname>Coorens</surname><given-names>THH</given-names></name><name><surname>Hooks</surname><given-names>Y</given-names></name><name><surname>O’Neill</surname><given-names>L</given-names></name><etal/></person-group><article-title>Extensive heterogeneity in somatic mutation and selection in the human bladder</article-title><volume>370</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">33004514</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>L</given-names></name><name><surname>Leongamornlert</surname><given-names>D</given-names></name><name><surname>Coorens</surname><given-names>THH</given-names></name><name><surname>Sanders</surname><given-names>MA</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name><etal/></person-group><article-title>The mutational landscape of normal human endometrial epithelium</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>580</volume><issue>7805</issue><fpage>640</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">32350471</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coorens</surname><given-names>THH</given-names></name><name><surname>Moore</surname><given-names>L</given-names></name><name><surname>Robinson</surname><given-names>PS</given-names></name><name><surname>Sanghvi</surname><given-names>R</given-names></name><name><surname>Christopher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Extensive phylogenies of human development inferred from somatic mutations</article-title><volume>597</volume><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">34433963</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lee-Six</surname><given-names>H</given-names></name><name><surname>Olafsson</surname><given-names>S</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name><name><surname>Osborne</surname><given-names>RJ</given-names></name><name><surname>Sanders</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The landscape of somatic mutation in normal colorectal ep-ithelial cells</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>574</volume><issue>7779</issue><fpage>532</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">31645730</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Spencer Chapman</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>N</given-names></name><name><surname>Dawson</surname><given-names>KJ</given-names></name><name><surname>Mende</surname><given-names>N</given-names></name><etal/></person-group><article-title>Clonal dynamics of haematopoiesis across the human lifespan</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>606</volume><fpage>343</fpage><lpage>350</lpage><issue>7913</issue><pub-id pub-id-type="pmcid">PMC9177428</pub-id><pub-id pub-id-type="pmid">35650442</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-04786-y</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>LA</given-names></name><name><surname>Bowman</surname><given-names>RL</given-names></name><name><surname>Merlinsky</surname><given-names>TR</given-names></name><name><surname>Csete</surname><given-names>IS</given-names></name><name><surname>Ooi</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Single cell mutation analysis of clonal evolution in myeloid malignancies</article-title><volume>587</volume><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="pmcid">PMC7677169</pub-id><pub-id pub-id-type="pmid">33116311</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2864-x</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corces-Zimmerman</surname><given-names>MR</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name></person-group><article-title>Preleukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis</article-title><volume>28</volume><fpage>2276</fpage><lpage>2282</lpage><pub-id pub-id-type="pmcid">PMC4262622</pub-id><pub-id pub-id-type="pmid">25005245</pub-id><pub-id pub-id-type="doi">10.1038/leu.2014.211</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Jahn</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clonal evolution of acute myeloid leukemia revealed by high-throughput singlecell genomics</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>11</volume><issue>1</issue><elocation-id>5327</elocation-id><pub-id pub-id-type="pmcid">PMC7577981</pub-id><pub-id pub-id-type="pmid">33087716</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-19119-8</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ediriwickrema</surname><given-names>A</given-names></name><name><surname>Aleshin</surname><given-names>A</given-names></name><name><surname>Reiter</surname><given-names>JG</given-names></name><name><surname>Corces</surname><given-names>MR</given-names></name><name><surname>Köhnke</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single-cell mutational profiling enhances the clinical evaluation of AML MRD</article-title><volume>4</volume><fpage>943</fpage><lpage>952</lpage><pub-id pub-id-type="pmcid">PMC7065471</pub-id><pub-id pub-id-type="pmid">32150611</pub-id><pub-id pub-id-type="doi">10.1182/bloodadvances.2019001181</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jan</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>TM</given-names></name><name><surname>Corces-Zimmerman</surname><given-names>MR</given-names></name><name><surname>Vyas</surname><given-names>P</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><etal/></person-group><article-title>Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia</article-title><volume>4</volume><elocation-id>149ra118</elocation-id><pub-id pub-id-type="pmcid">PMC4045621</pub-id><pub-id pub-id-type="pmid">22932223</pub-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3004315</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majeti</surname><given-names>R</given-names></name></person-group><article-title>Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic hetero-geneity, PREPRINT (version 1)</article-title><pub-id pub-id-type="pmid">38467769</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Wahab</surname><given-names>OA</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differ-entiation</article-title><volume>18</volume><fpage>553</fpage><lpage>567</lpage><pub-id pub-id-type="pmcid">PMC4105845</pub-id><pub-id pub-id-type="pmid">21130701</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2010.11.015</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaidzik</surname><given-names>VI</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Späth</surname><given-names>D</given-names></name><name><surname>Habdank</surname><given-names>M</given-names></name><name><surname>Köhne</surname><given-names>CH</given-names></name><etal/></person-group><article-title>TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group</article-title><volume>30</volume><fpage>1350</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">22430270</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abelson</surname><given-names>S</given-names></name><name><surname>Collord</surname><given-names>G</given-names></name><name><surname>Ng</surname><given-names>SWK</given-names></name><name><surname>Weissbrod</surname><given-names>O</given-names></name><name><surname>Cohen</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Prediction of acute myeloid leukaemia risk in healthy individuals</article-title><volume>559</volume><fpage>400</fpage><pub-id pub-id-type="pmcid">PMC6485381</pub-id><pub-id pub-id-type="pmid">29988082</pub-id><pub-id pub-id-type="doi">10.1038/s41586-018-0317-6</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fabre</surname><given-names>MA</given-names></name><name><surname>de Almeida</surname><given-names>JG</given-names></name><name><surname>Fiorillo</surname><given-names>E</given-names></name><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Damaskou</surname><given-names>A</given-names></name><etal/></person-group><article-title>The longitudinal dynamics and natural history of clonal haematopoiesis</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>606</volume><issue>7913</issue><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="pmcid">PMC9177423</pub-id><pub-id pub-id-type="pmid">35650444</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-04785-z</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weinstock</surname><given-names>JS</given-names></name><name><surname>Gopakumar</surname><given-names>J</given-names></name><name><surname>Burugula</surname><given-names>BB</given-names></name><name><surname>Uddin</surname><given-names>MM</given-names></name><name><surname>Jahn</surname><given-names>N</given-names></name><etal/></person-group><article-title>Aberrant activation of TCL1a promotes stem cell expansion in clonal haematopoiesis</article-title><publisher-name>Nature Publishing Group</publisher-name><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmcid">PMC10360040</pub-id><pub-id pub-id-type="pmid">37046083</pub-id><pub-id pub-id-type="doi">10.1038/s41586-023-05806-1</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>NA</given-names></name><name><surname>Latorre-Crespo</surname><given-names>E</given-names></name><name><surname>Terradas-Terradas</surname><given-names>M</given-names></name><name><surname>Lemos-Portela</surname><given-names>J</given-names></name><name><surname>Purcell</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>28</volume><issue>7</issue><fpage>1439</fpage><lpage>1446</lpage><pub-id pub-id-type="pmcid">PMC9307482</pub-id><pub-id pub-id-type="pmid">35788175</pub-id><pub-id pub-id-type="doi">10.1038/s41591-022-01883-3</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>KL</given-names></name><name><surname>Ptashkin</surname><given-names>RN</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Braunstein</surname><given-names>L</given-names></name><name><surname>Devlin</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Cancer therapy shapes the fitness landscape of clonal hematopoiesis</article-title><publisher-name>Nature Publishing Group</publisher-name><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC7891089</pub-id><pub-id pub-id-type="pmid">33106634</pub-id><pub-id pub-id-type="doi">10.1038/s41588-020-00710-0</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKerrell</surname><given-names>T</given-names></name><name><surname>Vassiliou</surname><given-names>GS</given-names></name></person-group><article-title>Aging as a driver of leukemogenesis</article-title><volume>7</volume><elocation-id>306fs38</elocation-id><pub-id pub-id-type="pmcid">PMC4916992</pub-id><pub-id pub-id-type="pmid">26400908</pub-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aac4428</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>KL</given-names></name><name><surname>Ptashkin</surname><given-names>RN</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Braunstein</surname><given-names>L</given-names></name><name><surname>Devlin</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Oncologic therapy shapes the fitness landscape of clonal hematopoiesis</article-title></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Cancer genome landscapes</article-title><volume>339</volume><elocation-id>1546</elocation-id><pub-id pub-id-type="pmcid">PMC3749880</pub-id><pub-id pub-id-type="pmid">23539594</pub-id><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jassim</surname><given-names>A</given-names></name><name><surname>Rahrmann</surname><given-names>EP</given-names></name><name><surname>Simons</surname><given-names>BD</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name></person-group><article-title>Cancers make their own luck: theories of cancer origins</article-title><volume>23</volume><fpage>710</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">37488363</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tomasetti</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention</article-title><publisher-name>American Association for the Advancement of Science</publisher-name><volume>355</volume><fpage>1330</fpage><lpage>1334</lpage><pub-id pub-id-type="pmcid">PMC5852673</pub-id><pub-id pub-id-type="pmid">28336671</pub-id><pub-id pub-id-type="doi">10.1126/science.aaf9011</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Abascal</surname><given-names>F</given-names></name><name><surname>Harvey</surname><given-names>LMR</given-names></name><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Lawson</surname><given-names>ARJ</given-names></name><name><surname>Lensing</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Somatic mutation landscapes at single-molecule resolution</article-title><publisher-name>Nature Publishing Group</publisher-name><volume>593</volume><fpage>405</fpage><lpage>410</lpage><issue>7859</issue><pub-id pub-id-type="pmid">33911282</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Challen</surname><given-names>GA</given-names></name><name><surname>Birmann</surname><given-names>BM</given-names></name><name><surname>Druley</surname><given-names>TE</given-names></name></person-group><article-title>Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults</article-title><volume>7</volume><elocation-id>12484</elocation-id><pub-id pub-id-type="pmcid">PMC4996934</pub-id><pub-id pub-id-type="pmid">27546487</pub-id><pub-id pub-id-type="doi">10.1038/ncomms12484</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Tong</surname><given-names>RS</given-names></name><name><surname>Birmann</surname><given-names>BM</given-names></name><name><surname>Druley</surname><given-names>TE</given-names></name></person-group><article-title>Clonal haematopoiesis and risk of acute myeloid leukemia. haematol.2018.215269</article-title></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jongen-Lavrencic</surname><given-names>M</given-names></name><name><surname>Grob</surname><given-names>T</given-names></name><name><surname>Hanekamp</surname><given-names>D</given-names></name><name><surname>Kavelaars</surname><given-names>FG</given-names></name><name><surname>Hinai</surname><given-names>Aa</given-names></name><etal/></person-group><article-title>Molecular minimal residual disease in acute myeloid leukemia</article-title><pub-id pub-id-type="pmid">29601269</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="book"><collab>mission bio</collab><source>2020, tapestri single-cell DNA sequencing re-quirements guide</source><publisher-name>Library Catalog</publisher-name><date-in-citation>accessed june 2020</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://support.missionbio.com">support.missionbio.com</ext-link></comment></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><article-title>Cutadapt removes adapter sequences from high- throughput sequencing reads</article-title><volume>17</volume><fpage>10</fpage></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><article-title>Trimmomatic: a flexible trimmer for illumina sequence data</article-title><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="pmcid">PMC4103590</pub-id><pub-id pub-id-type="pmid">24695404</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name><etal/></person-group><article-title>TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions</article-title><volume>14</volume><fpage>R36</fpage><pub-id pub-id-type="pmcid">PMC4053844</pub-id><pub-id pub-id-type="pmid">23618408</pub-id><pub-id pub-id-type="doi">10.1186/gb-2013-14-4-r36</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pop</surname><given-names>M</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Ultrafast and memory-efficient alignment of short DNA sequences to the human genome</article-title><volume>10</volume><fpage>R25</fpage><pub-id pub-id-type="pmcid">PMC2690996</pub-id><pub-id pub-id-type="pmid">19261174</pub-id><pub-id pub-id-type="doi">10.1186/gb-2009-10-3-r25</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><etal/></person-group><article-title>The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data</article-title><volume>20</volume><fpage>1297</fpage><lpage>1303</lpage><comment>Company: Cold Spring Harbor Laboratory Press Distributor: Cold Spring Harbor Laboratory Press Institution: Cold Spring Harbor Laboratory Press Label: Cold Spring Harbor Laboratory Press Publisher: Cold Spring Harbor Lab</comment><pub-id pub-id-type="pmcid">PMC2928508</pub-id><pub-id pub-id-type="pmid">20644199</pub-id><pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DePristo</surname><given-names>MA</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Garimella</surname><given-names>KV</given-names></name><name><surname>Maguire</surname><given-names>JR</given-names></name><etal/></person-group><article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title><volume>43</volume><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="pmcid">PMC3083463</pub-id><pub-id pub-id-type="pmid">21478889</pub-id><pub-id pub-id-type="doi">10.1038/ng.806</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Auwera</surname><given-names>GA</given-names></name><name><surname>Carneiro</surname><given-names>MO</given-names></name><name><surname>Hartl</surname><given-names>C</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Del Angel</surname><given-names>G</given-names></name><etal/></person-group><article-title>From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline</article-title><volume>43</volume><elocation-id>11.10.1-11.10.33</elocation-id><pub-id pub-id-type="pmcid">PMC4243306</pub-id><pub-id pub-id-type="pmid">25431634</pub-id><pub-id pub-id-type="doi">10.1002/0471250953.bi1110s43</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schwede</surname><given-names>M</given-names></name><name><surname>Jahn</surname><given-names>K</given-names></name><name><surname>Kuipers</surname><given-names>J</given-names></name><name><surname>Miles</surname><given-names>LA</given-names></name><name><surname>Bowman</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity</article-title><publisher-name>Nature Publishing Group</publisher-name><fpage>1</fpage><lpage>10</lpage></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><title>Construction of phylogenetic trees from preleukemic haematopoietic stem cells from AML patients at diagnosis</title><p>(A) Preleukemic haematopoietic stem cells were sorted from bone marrow aspirate samples acquired from AML patients at diagnosis. The sorted samples were then passed onto the single-cell DNA sequencing platform for genotype information on a targeted panel of 45 commonly mutated myeloid genes. Variant information at single-cell level combined with bulk sequencing information of the same samples before sorting enables the assignment of individual cells to their respective clonal genotype. Phylogenetic trees were constructed for each patient based on the clonal architecture found in the preleukemic HSC population. <bold>(B-D)</bold> Three 4-hit phylogenetic trees from three patients are shown. Clones are denoted by circles and ordered on ascending arcs based on number of drivers detected. The number of cells assigned to each clone is labelled on the circle and replaced by a grey cross if zero. The genotype of a clone is also labelled and represented by a red star if it belongs to the blast genotype. <bold>(E)</bold> Across the 17 trees reconstructed for the 16 patients, 6 trees were identified as 4-hit events (including B-D), 9 trees were identified as 3-hit events (including the pair of technical replicate from patient ID12565, also see Supplementary Figure S15) and 2 trees were identified as 2-hit events. Samples that contain multiple <italic>k</italic>-th mutants, i.e. multiple possible AML blast genotypes, are marked with a †.</p></caption><graphic xlink:href="EMS192866-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>Statistics of preleukemic phylogenetic trees suggests pervasive positive selection operates during preleukemic evolution.</title><p>(A) A model of HSC dynamics as a multi-class branching process where stem cells self-renew symmetrically at rate 1/<italic>τ</italic> and acquire driver mutations stochastically at a rate of <italic>µ</italic> per year. Driver mutations confer a selective advantage <italic>s</italic> per year to the cell. Under the staircase model, every additional mutation confers an additional selective advantage to the lineage. <bold>(B)</bold> An example of the evolutionary dynamics observed in this model where cancer onset is defined by the first lineage that acquires <italic>k</italic> driver mutations with <italic>k</italic> = 4 in this example (red colouring). <bold>(C)</bold> The phylogenetic tree constructed from driver mutations at diagnosis can be used to extract the clone size vector <italic><bold>n</bold></italic> =(<italic>n</italic>0, <italic>n</italic><sub>1</sub>, <italic>n</italic><sub>2</sub>, <italic>n</italic><sub>3</sub>). <bold>(D)</bold> Stochastic simulations produced four thousand 3-hit and four thousand 4-hit virtual AML events diagnosed before age 80 per parameter combination. The clone size vectors of these simulated ‘virtual AMLs’ (<italic><bold>n</bold></italic><sup>′</sup>, pink lines) were compared against real trees (<italic><bold>n</bold></italic>, purple line) from our single-cell experiments using a similarity metric. <bold>(E, F)</bold> Set similarity (colour scale) between observed trees (purple lines) and closest simulated trees (pink lines) for different selection coefficients across the 12 observed trees considered.</p></caption><graphic xlink:href="EMS192866-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>Independent AML single-cell dataset<sup><xref ref-type="bibr" rid="R27">27</xref></sup> validates that moderate selection operates during preleukemic evolution.</title><p>Clone size vectors from an independent data set of 27 <italic>k</italic> = 3 single-cell AML trees from Morita et al.<sup><xref ref-type="bibr" rid="R27">27</xref></sup> (purple lines) compared to the closest ‘virtual AML’ clone size vectors generated from our stochastic simulations (pink lines) for three different selection strengths (panels). The normalised set similarity (colourscale) between all 27 trees and their closest simulated trees across the full set of selection strengths modelled is shown in the top panel.</p></caption><graphic xlink:href="EMS192866-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Individual trees show variation in inferred selection levels.</title><p><bold>(A)</bold> The 100 ‘virtual AML’ trees highest in similarity were identified for each observed tree. Sample 2225 is shown here. The inferred selection is visualized by the distribution of the number of ‘virtual AMLs’ across the underlying parameter distribution. <bold>(B)</bold> This procedure was carried out for 80 real trees, including 6 four-hit Poon trees, 7 three-hit Poon trees (containing a pair of technical replicate), 44 three-hit Morita trees and 23 four-hit Morita trees.</p></caption><graphic xlink:href="EMS192866-f004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><title>Early double-mutant and triple-mutant clones identify a high-risk group for AML transformation.</title><p><bold>(A)</bold> An example of the preleukemic clonal history of a simulated individual who acquires an AML-defining 4th-hit at age 60 where AML drivers confer moderate levels of positive selection. <bold>(B)</bold> Distribution of mutation acquisition times in simulated individuals (under moderate selection and at medium mutation level) who acquired 4th-hit before age 70. <bold>(C)</bold> Distribution of mutation acquisition times in unselected simulated individuals, showing marked differences compared to simulated individuals destined to develop AML. <bold>(D)</bold> The absolute risk of AML transformation before age 70 is dependent on when single (orange), double (green) and triple (purple) mutant clones are acquired. This is illustrated for the individual in (A) for whom the absolute risk jumps upwards (grey dashed line) whenever the individual acquired a further mutation (star).</p></caption><graphic xlink:href="EMS192866-f005"/></fig></floats-group></article>